Nasopharyngeal carcinoma (NPC) · line 1 · Induction gemcitabine-cisplatin (GC) + concurrent cisplatin chemoradiation (IMRT) — locoregionally advanced nasopharyngeal carcinoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-NPC-GC-INDUCTION-CCRT`

ID	`IND-NPC-1L-LOCALLY-ADVANCED-CCRT`
Type	Indication
Status	reviewed 2026-07-11
Diseases	`DIS-NPC`
Sources	`SRC-INTERGROUP-0099-ALSARRAF-1998` `SRC-NCCN-HNSCC-2025` `SRC-NPC-GC-INDUCTION-ZHANG-2019`

Notes

STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; dev-mode-exempted). Coverage-enabling locally-advanced indication for DIS-NPC. RT dose/fractionation intentionally not modeled as a formal RadiationCourse entity in this authoring pass (see REG-NPC-GC- INDUCTION-CCRT notes). Post-treatment EBV-DNA surveillance (RF-NPC-EBV-DNA-POST-TREATMENT-SURVEILLANCE) documented but not algorithmically wired — Phase 4 backlog.

Used By

Algorithms

ALGO-NPC-1L - ALGO-NPC-1L

Disease

DIS-NPC - Nasopharyngeal carcinoma (NPC)

Red flag

RF-NPC-EBV-DNA-POST-TREATMENT-SURVEILLANCE - Detectable or rising plasma EBV-DNA (BIO-EBV-DNA, quantitative PCR) after completion of d...